C4D antibody, targeting the complement component 4d (C4d), is a critical tool in diagnostic and research settings, particularly in transplant pathology and autoimmune diseases. C4d is a stable degradation product of complement component C4. generated during activation of the classical complement pathway. Unlike its precursors, C4d covalently binds to nearby tissues, serving as a durable marker of complement activation.
In transplantation, C4d staining is widely used to diagnose antibody-mediated rejection (AMR) in organs like kidneys and hearts. When donor-specific antibodies bind to graft endothelium, they activate the complement cascade, leaving C4d deposits detectable via immunohistochemistry or immunofluorescence. Its presence in peritubular capillaries (in kidney transplants) or myocardial tissue (in heart transplants) correlates with poor graft outcomes, guiding immunosuppressive therapy.
In autoimmune contexts, C4d is studied in conditions like systemic lupus erythematosus (SLE), where it deposits in affected tissues (e.g., skin, kidneys) and reflects disease activity. It also aids in diagnosing autoimmune blistering disorders, such as bullous pemphigoid, by highlighting complement activation at the dermo-epidermal junction.
Despite its utility, C4d interpretation requires caution. False positives/negatives may arise from technical factors or non-specific binding. Ongoing research explores its role in prognostic stratification and therapeutic monitoring, emphasizing its value as a biomarker of humoral immunity.